Nordmeyer Johannes, Coats Louise, Bonhoeffer Philipp
The Cardiac Unit, Institute of Child Health and Great Ormond Street Hospital for Children, London, United Kingdom.
Semin Thorac Cardiovasc Surg. 2006 Summer;18(2):122-5. doi: 10.1053/j.semtcvs.2006.07.006.
Transcatheter valve replacement has recently been introduced into clinical practice and has the potential to transform the management of valvular heart disease. To date, the largest human experience exists with percutaneous pulmonary valve implantation in patients with repaired congenital heart disease who require re-intervention to the right ventricular outflow tract. The application of this approach, however, is presently restricted to certain right ventricular outflow tract morphologies, because the device needs to be anchored safely to prevent device dislodgement. Early results of percutaneous pulmonary valve implantation show lower morbidity than surgery and significant early symptomatic improvement. In the future, the challenge will be to extend percutaneous pulmonary valve implantation to all patients with a clinical indication to delay or avoid repeat open-heart surgery.
经导管瓣膜置换术最近已引入临床实践,有可能改变心脏瓣膜病的治疗方式。迄今为止,在需要对右心室流出道进行再次干预的先天性心脏病修复患者中,经皮肺动脉瓣植入术拥有最大规模的人体应用经验。然而,由于该装置需要安全固定以防止移位,目前这种方法的应用仅限于某些右心室流出道形态。经皮肺动脉瓣植入术的早期结果显示,其发病率低于手术,且早期症状有显著改善。未来的挑战将是把经皮肺动脉瓣植入术推广到所有有临床指征、需要延迟或避免再次进行心脏直视手术的患者。